RecruitingNCT07349277
Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Evaluation of sFlt-1/PlGF Ratio, Osteoprotegerin (OPG) and Soluble Endoglin (sEng) as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Sponsor
Ammar Jassim Abed
Enrollment
120 participants
Start Date
Oct 10, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Eligibility
Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years
Inclusion Criteria3
- Pregnant women between 20 and 36 weeks of gestation
- Age between 18 and 45 years
- Attending the antenatal clinic at the study site
Exclusion Criteria5
- Chronic hypertension
- Renal disease
- Diabetes mellitus
- Multiple gestations
- Autoimmune disorders
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07349277
Related Trials
Placental Imaging Techniques
NCT068613091 location
Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy
NCT0348718514 locations
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
NCT067851161 location
Vascular Effects of High-Salt After Preeclampsia
NCT067494181 location
Effects of High Altitude on AMPK Activation
NCT023915191 location